Background: Altered expression of the BCL-2 family member MCL-1 has been linked to the progression and outcome of various malignancies. Recently, MCL-1 inhibitor S63845 was reported to kill MCL-1-dependent cancer cells and has potential value in clinical application. Purpose: Herein, we reported MCL-1 expression pattern in Chinese de novo acute myeloid leukemia (AML) and its impact on prognosis and may provide theoretical basis for AML patients using MCL-1 inhibitor in clinics. Real-time quantitative PCR was carried out to detect the transcript of MCL-1 in AML patients. Results: MCL-1 expression was significantly up-regulated in AML compared with controls (P=0.042). We divided the patients into two groups (higher and lower expression of MCL-1) based on the median level. Among both non-acute promyelocytic leukemia (APL) and cytogenetically normal AML (CN-AML), patients with higher expression of MCL-1 correlated with lower complete remission (CR) rate (P=0.031 and 0.004, respectively) and shorter overall survival (OS) time (P=0.008 and 0.004, respectively) compared with those with lower expression of MCL-1. Meanwhile, Cox regression analyses revealed that overexpression of MCL-1 acted as an independent risk factor for OS in non-APL patients and CN-AML patients (P=0.011 and 0.045, respectively). In follow-up patients, MCL-1 expression level decreased after CR compared with newly diagnosis time (P=0.020) and increased after relapse (P=0.004). Conclusion: Our findings suggest that higher expression of MCL-1 predicts poor prognosis and can be used for disease monitoring.
Introduction
Acute myeloid leukemia (AML), a molecularly and clinically heterogeneous disease, is characterized by differentiation arrest and uncontrolled proliferation of myeloid progenitor cells, which ultimately interferes with the production of normal blood cells. 1 Although recent treatment advances in hematopoietic stem cell transplantation and intensive chemotherapy, the clinical outcome for AML remained unsatisfied. 2 Since treatment with all-trans retinoic acid (ATRA) has dramatically improved the outcome of acute promyelocytic leukemia (APL) by binding to retinoic acid receptor α, the development of molecular risk-adapted treatment strategies and targeted therapies may improve the clinical outcome of AML.
targets for AML therapy. B-cell leukemia/lymphoma-2 (BCL-2) protein family consists of a pro-survival group and two pro-apoptotic subgroups. The pro-survival group comprise BCL-2, myeloid cell leukemia-1 (MCL-1), BCL-2 and BCL-2-like protein 1 isoform 1 (BCL-XL), which play important roles in regulating cell apoptosis, proliferation, differentiation and tumorigenesis. [4] [5] [6] [7] [8] Among them, MCL-1, isolated from a human myeloblastic leukemia cell line, can affect the development of tumor through the expression of its mRNA and protein in many cancers. [9] [10] [11] Allen et al indicated that overexpression of MCL-1 was related to poor overall survival (OS) in nonsmall cell lung cancer when MYC was up-regulated simultaneously. 6 In breast cancer, MCL-1 high-expressed was associated with later tumor stage and worse survival. 12 Glaser et al also found that knockdown of MCL-1, but not loss or pharmacological blockade of BclxL, Bcl-2 or Bcl-w, caused the death of transformed AML and could cure disease in AML-afflicted mice. 13 Recently, MCL-1 protein inhibitor S63845 was reported to kill MCL-1-dependent cancer cells and has potential value in clinical application. 14 Herein, we aimed to investigate the MCL-1 expression pattern as well as its clinical implication in Chinese de novo patients with AML and may provide theoretical basis for AML patients using MCL-1 protein inhibitor in clinics. 
Materials and methods Patients
Gene mutation Results
MCL-1 expression in controls and AML patients
As is shown in Figure 1 Figure 1 ).
Discriminative capacity of MCL-1 expression
ROC was used to evaluate the discriminative capacity of MCL-1 expression. It revealed that MCL-1 expression could act as a potential biomarker for distinguishing whole-cohort AML (AUC=0.625, 95% CI: 0.526-0.723, P=0.043, Figure 2A ), non-APL AML (AUC=0.676, 95% CI: 0.577-0.774, P=0.005, Figure 2B ) and CN-AML (AUC=0.636, 95% CI: 0.515-0.756, P=0.044, Figure 2C ) from normal controls.
Clinical and laboratory characteristics of AML patients Table 1 ). In addition, we further showed MCL-1 transcript level between the patients with and without CR (P=0.002, Figure 3) . Apart from APL patients, MCL-1 high cases also had markedly lower CR rate than MCL-1 low cases (26% vs 47%, P=0.031, Table 1 ). There was also a significant difference in CR rate between the two groups in CN-AML (23% vs 60%, P=0.004, Table 1 ).
Correlation between MCL-1 expression and clinical outcome
To investigate the prognostic significance of MCL-1 expression in AML, 141 AML patients with followup data (median 8 months, range 1-115 months) were included in survival analysis. Due to independent disease entity, APL was excluded from the analysis. Kaplan-Meier analyses revealed that there was a significant difference in OS time between MCL-1 high and MCL-1 low groups in non-APL patients (median 4 vs 9 months, respectively, P=0.008, Figure 4A ). MCL-1 high patients also had a shorter OS time than MCL-1 low patients in CN-AML patients (median 3 vs 16.5 months, respectively, P=0.004, Figure 4B ). In addition, multivariate analysis, including variables (age (>60/≤60y), WBC (≥30/<30*10 9 /L), MCL-1 expression (high/low) and gene mutations) with P<0.200 in univariate analysis, demonstrated that increased expression of MCL-1 was an independent adverse prognostic factor for OS among both non-APL and CN-AML patients (Tables 2 and 3) . However, there was no significant difference in LFS between two groups both in non-APL (P=0.157) and CN-AML patients (P=0.228).
To further validate the prognostic impact of MCL-1 expression in CN-AML patients, we focused on the GEP Figure 3 The comparison of MCL-1 expression among AML patients with and without CR. MCL-1 expression among AML patients (n=62, range 0.0000-105.5293, median 3.9643) who could achieve CR was significantly lower than those who could not achieve CR (n=79, range 0.0000-311.0063, median 15.5237) after induction therapy. Abbreviations: AML, acute myeloid leukemia; CR, complete remission. data (accession number GSE12417) using the online web tool Genomicscape. 21 MCL-1 high cases showed shorter OS time than MCL-1 low cases in two independent cohorts of CN-AML patients (P=0.022 and P=0.007, respectively, Figure 5 ).
Surveillance of MCL-1 expression in follow-up AML patients
To investigate whether the expression of MCL-1 could monitor disease recurrence in AML, we assessed MCL-1 OS_days OS_days A B Figure 5 Prognostic value of MCL-1 expression validated by public database. Gene expression profiling (GEP) data (accession number GSE12417, http://www.ncbi.nlm.nih. gov/geo/) was used to validate the prognostic value of MCL-1 expression in two independent cohorts of 162 and 78 cytogenetically normal AML (CN-AML) patients by the online web tool Genomicscape (http://genomicscape.com/microarray/survival.php).
expression in 52 AML patients in CR and 23 cases in relapse. The median MCL-1 levels in patients at CR and relapse were 3.194 (range 0.000 to 76.368) and 12.076 (range 0.216-151.220), respectively. Obviously, MCL-1 expression was significantly decreased in CR time and was significantly increased in relapsed time compare with initial diagnosis time (P=0.020 and P=0.004, respectively, Figure 6 ). In addition, the dynamic change of MCL-1 expression in the five paired AML patients of different stages ( Figure 7 ).
Discussion
Accumulating studies stated that MCL-1 expression was associated with the progression and outcome of various human malignant tumors. [4] [5] [6] In multiple myeloma, MCL-1 high-expression was reported to be associated with relapse and shorter event-free survival. 11 Mylin et al demonstrated that MCL-1 was up-regulated in multiple myeloma compared with monoclonal gammopathy of undetermined significance, but had no impact on OS and event-free survival. 22 Moreover, the activated vascular endothelial growth factor induced the overexpression of MCL-1 and predicted a poor outcome and aggressive disease progression in nonHodgkin's lymphoma. 23 More interestingly, Kempkensteffen et al elucidated that the antiapoptotic fulllength splicing variant of MCL-1, down-regulation in clearcell renal cancer, was related with poor tumor differentiation and predicted a higher risk for relapse; they also revealed that low MCL-1L was associated with short recurrence-free and disease-specific survival. 24 Glaser et al used RNAi for knockdown of MCL-1 to determine that MCL-1 was essential for development and sustained growth of this hematological malignancy and it could be targeted for therapeutic benefit. 13 In this study, we observed that up-regulation of MCL-1 expression was a frequent event in Chinese de novo AML patients. Survival analyses revealed that high MCL-1 expression was associated with shorter OS both in non-APL and in CN-AML patients. Notably, our data showed that highexpression of MCL-1 had lower CR rate. Meanwhile, expression of MCL-1 in CR and relapsed patients illustrated that MCL-1 were significantly decreased from the initial diagnosis to CR and increased after relapsed. These results together indicated that MCL-1 expression was a valuable predictor in assessing treatment outcome as well as status,and might serve as a criterion for the therapeutic evaluation in AML.
It has been well demonstrated that BCL-2 family proteins act as positive or negative regulators on cellular apoptosis and druggable targets. [4] [5] [6] [7] [8] [9] [10] [11] 25 Kaufmann et al found that cells overexpressing MCL-1 were resistant to a variety of chemotherapeutic agents and raised the possibility that some chemotherapeutic regimens might select for leukemia cells with elevated levels of this particular apoptosis inhibitor. 26 Recently, ABT-199, a highly potent and selective inhibitor of BCL-2, has been granted breakthrough designation by FDA for relapsed or refractory chronic lymphocytic leukemia with 17p deletion. 27 Moreover, Pan et al found that ABT-199 also potently killed a diverse array of AML cell lines by establishing an aggressive mouse xenograft model of MOLM-13.
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Notably, some scholars stated that MCL-1 induced the resistance to ABT-737 (the first molecule studied extensively preclinically) and its analogs ABT-263 (the first of this series to enter the clinic) and ABT-199, [28] [29] [30] while MCL-1 suppression could restore sensitivity to these compounds in leukemia cells, 31, 32 suggesting that drug resistance was attributed to high level of MCL-1. Kotschy et al found that the selective MCL-1 inhibitor S63845 killed MCL-1-dependent cancer cells by activating the BAX/BAK-dependent mitochondrial apoptotic pathway in diverse cancer models. 14 Doi et al showed that maritoclax, a novel kind of BCL-2 family inhibitors, induced the selective degradation of MCL-1 through the proteasome to kill AML cells that express elevated levels of MCL-1. 33 Recently, Wang et al revealed that inhibition of CDK9, a key component of the positive transcriptional regulator complex pTEFb which activates transcription via phosphorylation of RNA polymerase II, blocked transcription resulting in the repression of short-lived proteins such as MCL-1. 34 Dey J et al found that voruciclib, a novel CDK9
inhibitor which addressed a well-characterized key-mediator of resistance to venetoclax by repressing MCL-1, and the BCL-2 specific inhibitor, venetoclax, with promise for treating high-risk subtype of diffuse large B-cell lymphoma by establishing specific models. 35 Previous researches proved that higher levels of MCL-1 have been reported to result in the failure to achieve CR after fludarabine and chlorambucil treatment, 36,37 while higher MCL-1/BAX ratio was related to poor response to rituximab in some patients. 38 Taken together, these results suggested that MCL-1 combined with other targets have great potential in AML targeted therapies. In addition, our study further observed that MCL-1 overexpression was associated with NPM1 mutation, which was a favorable prognostic indicator in AML and frequently occurred in patients with normal karyotype. 39 In some studies, AML patients with NPM1 mutation appeared to benefit from ATRA as an adjunct to conventional chemotherapy. 40, 41 Moreover, it was reported that AML cells carrying NPM1 mutation were more sensitive to ATO, because of the expression of NPM1 mutant protein and its acquired C-terminus cysteine 288. 42 Martelli et al also showed that ATO/ATRA induced proteasomedependent degradation of NPM1 leukemic protein leading to cell growth inhibition and apoptosis in NPM1-mutated AML. 43 Although a large number of findings suggest that the NPM1 mutation has a favorable effect on the outcome for AML. [44] [45] [46] [47] Falini et al found that NPM1 exon 12 mutations which caused cytoplasmic dislocation of NPM were related to the malignant clone and leukemogenesis. 48 Moreover, a study conducted by Konoplev et al suggested that NPM1 mutations did not impact OS and event-free survival (EFS) in AML patients. 49 However, Verhaak et al demonstrated that patients with intermediate cytogenetic risk AML with NPM1 mutations had a significantly better OS and EFS than those without NPM1 mutations. 44 Further studies are needed to confirm and reveal the underlying association between MCL-1 expression and NPM1 mutation. Collectively, these results demonstrated that MCL-1 is overexpressed and confers a poor prognosis in Chinese de novo AML patients and could be also used as a potential therapeutic target in the treatment of newly diagnosed and relapsed AML.
Abbreviation list
AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; ATRA, all-trans retinoic acid; AUC, area under the ROC curve; BCL-2, B-cell leukemia/lymphoma-2; BCL-XL, BCL-2 and BCL-2-like protein 1 isoform 1; BM, Bone marrow; BMMNCs, BM mononuclear cells; CN-AML, cytogenetically normal AML; CR, complete remission; GEP, melting analysis; LFS, leukemia-free survival; MCL-1, myeloid cell leukemia-1; OS, overall survival; PLT, platelets; RARα, retinoic acid receptor α; ROC, Receiver operating characteristic curve; RQ-PCR, Real-time quantitative PCR; WBC, white blood cell; WHO, World Health Organization.
Ethics Statements
We confirm in the revised manuscript that a parent or legal guardian provided written informed consent for any patient under 18 years of age, and that this study was conducted in accordance with the Declaration of Helsinki. 
